Science and technology company Merck has opened a new packaging facility at its biotech manufacturing site in Aubonne, Switzerland.
The new building will be used for visual inspection and packaging processes, as well as shipping the company’s biotech medicines to more than 150 countries.
The facility will also enable Merck to carry out ongoing and future product launches.
Merck executive board chairman and CEO Stefan Oschmann said: “This state-of-the-art new packaging building demonstrates Merck's technological leadership in biotech manufacturing.
“With Aubonne and nearby Vevey, Switzerland is our prime hub for the manufacturing of biotech medicines for patients all over the world. It plays an instrumental role in the growth of our Healthcare business sector and the launch of new products.”
The new building is equipped with fully automated machinery and robotised logistics, which will allow it to process more than 12 million boxes of medicine and four million injection devices annually.
Merck noted that the facility is designed to adhere to international quality, environment, health and safety standards.
Since 2015, the company has invested nearly CHF27m ($28m) in the facility's construction.
The building is one of a series of investments by Merck over the past ten years in Switzerland, which amounts to more than CHF1bn ($1.04bn).
The company currently employs around 2,000 people across its 11 locations in the country, which include more than 700 in Aubonne.
Image: Merck officials during the inauguration ceremony of the new packaging building at Swiss Biotech Manufacturing Site of Aubonne. Photo: courtesy of PRNewsfoto / Merck.